Comparative Pharmacology
Head-to-head clinical analysis: HEPATASOL 8 versus NEPHRAMINE 5 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPATASOL 8 versus NEPHRAMINE 5 4.
HEPATASOL 8% vs NEPHRAMINE 5.4%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HEPATASOL 8% (amino acid injection) provides essential and non-essential amino acids to support protein synthesis and correct nitrogen balance in hepatic encephalopathy. It reduces plasma ammonia levels by promoting urea cycle activity and decreasing aromatic amino acids.
Provides essential amino acids for protein synthesis in patients with renal impairment, reducing nitrogen waste accumulation.
Intravenous infusion of 500 mL (40 g amino acids) over 3-4 hours, administered once daily or as directed by clinical response.
500 mL to 1000 mL intravenously over 8-24 hours, containing 5.4% amino acids, typically as a component of total parenteral nutrition; dose adjusted based on metabolic needs and protein requirements (usual 0.8-1.5 g/kg/day amino acids).
None Documented
None Documented
Approximately 30-60 minutes for individual amino acids; clinical context: rapid clearance supports continuous infusion to maintain plasma levels.
1-2 hours (endogenous amino acid pool turnover); clinical context: continuous infusion required to maintain plasma levels.
Renal: >95% of administered amino acids are reabsorbed and metabolized; negligible unchanged excretion. Biliary/fecal: <5%
Renal: >90% as amino acids and metabolites. Biliary/fecal: negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution